Abstracts tagged "Cutaneous manifestations"

Abstract Number: 1462 • 2015 ACR/ARHP Annual Meeting
Farber Disease: Important Differential Diagnostic Information for JIA and Other Inflammatory Arthritis Phenotypes Is Revealed By Data from the Largest Clinical Cohort to Date
Alexander Solyom¹, Boris Huegle², Bo Magnusson³, Balahan Makay⁴, Nur Arslan⁵, John Mitchell⁶, Pranoot Tanpaiboon⁷, Norberto Guelbert⁸, Ratna Puri⁹, Lawrence Jung¹⁰, Giedre Grigelioniene¹¹, Karoline Ehlert¹², Michael Beck¹³, Calogera Simonaro¹⁴ and Edward Schuchman¹⁵, ¹Pediatrics, University of Pecs, Pecs, Hungary, ²Pediatric Rheumatology, German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ³Pediatric Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ⁴Pediatric Rheumatology, Eylul University, Izmir, Turkey, ⁵Eylul University, Izmir, Turkey, ⁶Pediatric Endocrinology, Montreal Children's Hospital, Montreal, QC, Canada, ⁷Genetics and Metabolism, Children's National Medical Center, Washington, DC, ⁸Metabolic Diseases Section, Children’s Hospital of Cordoba, Cordoba, Argentina, ⁹Medical Genetics, Sir Ganga Ram Hospital, New Delhi, India, ¹⁰Pediatric Rheumatology, Children's National Med Ctr, Washington, DC, ¹¹Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden, ¹²University Medical Center - Greifswald, Greifswald, Germany, ¹³Institute of Human Genetics, University Medical Center - Mainz, Mainz, Germany, ¹⁴Genetics and Genomic Sciences, Icahn School of Medicine at Mt. Sinai, New York, NY, ¹⁵Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Farber disease (Farber lipogranulomatosis; acid ceramidase deficiency) is a rare lysosomal storage disorder resulting from the inherited deficiency of the enzyme acid ceramidase due…
Abstract Number: 3033 • 2015 ACR/ARHP Annual Meeting
Polyarteritis Nodosa and Cutaneous Arteritis: Are They Distinct Diseases?
Fatma Alibaz-Oner¹, Matthew J. Koster², Cynthia S. Crowson³, Ashima Makol², Steven R. Ytterberg², Eric L. Matteson² and Kenneth J. Warrington², ¹Department Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Polyarteritis nodosa (PAN) is a rare systemic necrotizing vasculitis predominantly targeting medium-sized visceral arteries. Cutaneous arteritis (CA) is generally limited to the medium-sized vessels…
Abstract Number: 2776 • 2014 ACR/ARHP Annual Meeting
Drug-Associated Cutaneous Vasculitis: Study of 239 Patients from a Single Referral Center
Montserrat Santos-Gómez¹, Francisco Ortiz Sanjuan¹, Ricardo Blanco¹, Jose L. Hernández², Vanesa Calvo-Río¹, Javier Loricera¹, Carmen Gonzalez-Vela³, Trinitario Pina Murcia⁴, Hector Fernandez-Llaca⁵, Susana Armesto⁵, Victor Martínez-Taboada¹, Javier Rueda-Gotor¹, Leyre Riancho-Zarrabeitia¹ and Miguel A. González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ⁴Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ⁵Dermatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain
Background/Purpose The 2012 International Chapel Hill Consensus Conference on the Nomenclature of Vasculitides defined drug-associated immune complex vasculitis as a distinct entity included within the…
Abstract Number: 804 • 2014 ACR/ARHP Annual Meeting
Vasculitis and Inflammatory Bowel Diseases: A Study of 32 Patients with Both Conditions and Systematic Review of the Literature
Alice Sy¹, Natasha Dehghan², Nader A. Khalidi³, Lillian Barra⁴, Simon Carette⁵, David Cuthbertson⁶, Gary S. Hoffman⁷, Curry L Koening⁸, Carol A. Langford⁹, Carol McAlear¹⁰, Paul A. Monach¹¹, Larry W. Moreland¹², Philip Seo¹³, Ulrich Specks¹⁴, Steven R. Ytterberg¹⁵, Gert Van Assche¹⁶, Peter A. Merkel¹⁰ and Christian Pagnoux⁵, ¹Medicine Division, London, ON, Canada, ²Rheumatology Division, Vancouver, BC, Canada, ³Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ⁴Rheumatology, St. Joseph's Health Care, London, ON, Canada, ⁵Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁶Department of Biostatistics, University of South Florida, Tampa, FL, ⁷Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁸Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, ⁹Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Rheumatology, Boston University, Boston, MA, ¹²Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹³Johns Hopkins Vasculitis Center, Rheumatology Division, Johns Hopkins University, Baltimore, MD, ¹⁴Mayo Clinic, Rochester, MN, ¹⁵Rheumatology Division, Mayo Clinic, Rochester, MN, ¹⁶Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Small case series suggested that vasculitis and inflammatory bowel disease (IBD; Crohn’s disease [CD] or ulcerative colitis [UC]) can co-occur more commonly than the…
Abstract Number: 1548 • 2012 ACR/ARHP Annual Meeting
Cutaneous Vasculitis as a Paraneoplastic Syndrome
Javier Loricera¹, Vanesa Calvo-Rio², Francisco Ortiz Sanjuan³, Marcos Antonio Gonzalez-Lopez⁴, Hector Fernandez-Llaca⁴, Javier Rueda-Gotor², Carmen Gonzalez-Vela⁵, Cristina Mata-Arnaiz³, Miguel A. Gonzalez-Gay² and Ricardo Blanco², ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ⁴Dermatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ⁵Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain
Background/Purpose: Cutaneous Leukocytoclastic Vasculitis (CLV) may be associated with malignancies, and sometimes it behaves as a paraneoplastic syndrome. This association has been reported in a…
Abstract Number: 1507 • 2012 ACR/ARHP Annual Meeting
Propylthiouracil Reduces Fibrosis in Chronic Oxidant Stress Mouse Model of Scleroderma
Gianluca Bagnato¹, Alessandra Bitto², Natasha Irrera², Gabriele Pizzino², Neal Roberts³, Maurizio Cinquegrani⁴, Donatella Sangari¹, Francesco Squadrito², Gianfilippo Bagnato¹ and Antonino Saitta⁴, ¹Rheumatology, University of Messina, Messina, Italy, ²Pharmacology, University of Messina, Messina, Italy, ³Medical College of Virginia, Richmond, VA, ⁴Internal Medicine, University of Messina, Messina, Italy
Background/Purpose: Systemic sclerosis (SSc) is characterized by fibrosis of skin and visceral organs; vascular damage and resultant ischemia; and immunological dysregulation manifested by autoantibodies. Hypothyroidism,…
Abstract Number: 1508 • 2012 ACR/ARHP Annual Meeting
Simvastatin Attenuates Pulmonary Fibrosis in a Murine Model of Systemic Sclerosis
Gianluca Bagnato¹, Alessandra Bitto², Natasha Irrera², Gabriele Pizzino², Donatella Sangari¹, Maurizio Cinquegrani³, Neal Roberts⁴, Gianfilippo Bagnato¹, Francesco Squadrito² and Antonino Saitta³, ¹Rheumatology, University of Messina, Messina, Italy, ²Pharmacology, University of Messina, Messina, Italy, ³Internal Medicine, University of Messina, Messina, Italy, ⁴Medical College of Virginia, Richmond, VA
Background/Purpose: Simvastatin is best known for its antilipidemic action due to its inhibition of 3-hydroxy-3-methylglutaryl CoenzymeA (HMG CoA) reductase. Inhibition of biological precursors in this pathway also…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].